Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent HGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a ...

Shares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash. Century has ...

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently ...

NEEDHAM, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...

An announcement from Candel Therapeutics ( (CADL)) is now available. Candel Therapeutics has reported promising results from its ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade ...

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday potentially driven by continued momentum following the company’s announcement of positive phase 3 trial results for its ...

Candel Therapeutics, Inc. has announced an underwritten public offering to raise $80 million through the sale of its common stock and pre-funded warrants. The company plans to use the proceeds to ...